{"transactions":[{"id":4616501,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T23:45:59.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":585,"price":6.0243,"value":3524.2155,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (\"MGC 2018 QP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held directly by MGC 2018 QP."}],"balance_after":624765,"source":{"system":"sec-edgar","filing":"0001193125-26-389545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1914883/000119312526389545/ownership.xml","form_type":"4"}},{"id":4616500,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-11T23:45:59.000Z","date":"2026-09-09","kind":"sale","planned":true,"acquired":false,"shares":523,"price":6.0243,"value":3150.7089,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.02 to $6.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 LP."}],"balance_after":557467,"source":{"system":"sec-edgar","filing":"0001193125-26-389545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1914883/000119312526389545/ownership.xml","form_type":"4"}},{"id":3665751,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T23:42:53.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":5294,"price":6.0183,"value":31860.8802,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (\"MGC 2018 QP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held directly by MGC 2018 QP."}],"balance_after":625350,"source":{"system":"sec-edgar","filing":"0001193125-26-385511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1914883/000119312526385511/ownership.xml","form_type":"4"}},{"id":3665750,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T23:42:53.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":4725,"price":6.0183,"value":28436.4675,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 LP."}],"balance_after":557990,"source":{"system":"sec-edgar","filing":"0001193125-26-385511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1914883/000119312526385511/ownership.xml","form_type":"4"}},{"id":3665749,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T23:42:53.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":3223,"price":6.0698,"value":19562.9654,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (\"MGC 2018 QP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held directly by MGC 2018 QP."}],"balance_after":630644,"source":{"system":"sec-edgar","filing":"0001193125-26-385511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1914883/000119312526385511/ownership.xml","form_type":"4"}},{"id":3665748,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-08T23:42:53.000Z","date":"2026-09-03","kind":"sale","planned":true,"acquired":false,"shares":2877,"price":6.0698,"value":17462.8146,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.000 to $6.085, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 LP."}],"balance_after":562715,"source":{"system":"sec-edgar","filing":"0001193125-26-385511","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1914883/000119312526385511/ownership.xml","form_type":"4"}},{"id":681613,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T21:58:27.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":18706,"price":6.0082,"value":112389.3892,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners QP 2018, LP (\"MGC 2018 QP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held directly by MGC 2018 QP."}],"balance_after":633867,"source":{"system":"sec-edgar","filing":"0001193125-26-357225","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526357225/ownership.xml","form_type":"4"}},{"id":681612,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T21:58:27.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":16696,"price":6.0082,"value":100312.9072,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on April 23, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price for multiple transactions ranging from $6.00 to $6.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the price range reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 LP."}],"balance_after":565592,"source":{"system":"sec-edgar","filing":"0001193125-26-357225","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526357225/ownership.xml","form_type":"4"}},{"id":830920,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:02:13.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120200/ownership.xml","form_type":"4"}},{"id":830919,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:02:13.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":23742,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":23742,"derivative":{"exercise_price":3.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0001193125-26-120200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120200/ownership.xml","form_type":"4"}},{"id":830918,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:02:13.000Z","date":"2026-03-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":20724},"source":{"system":"sec-edgar","filing":"0001193125-26-120200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120200/ownership.xml","form_type":"4"}},{"id":830917,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-03-23T23:02:13.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":20724,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"Premium End Date\" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The \"Premium End Date\" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested."}],"balance_after":20724,"derivative":{"exercise_price":3.91,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":20724},"source":{"system":"sec-edgar","filing":"0001193125-26-120200","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526120200/ownership.xml","form_type":"4"}},{"id":888256,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-23T21:29:27.000Z","date":"2026-02-20","kind":"grant","planned":false,"acquired":true,"shares":20400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on February 20, 2027, subject to the Reporting Person providing continuous service through such date."}],"balance_after":20400,"derivative":{"exercise_price":1.04,"expiration_date":"2036-02-19","underlying":"Common Stock","underlying_shares":20400},"source":{"system":"sec-edgar","filing":"0001193125-26-064103","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526064103/ownership.xml","form_type":"4"}},{"id":1135583,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-23T21:04:25.000Z","date":"2025-05-22","kind":"grant","planned":false,"acquired":true,"shares":19111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on March 31, 2026, subject to the Reporting Person providing continuous service through such date."}],"balance_after":19111,"derivative":{"exercise_price":1.19,"expiration_date":"2035-05-21","underlying":"Common Stock","underlying_shares":19111},"source":{"system":"sec-edgar","filing":"0000950170-25-077073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025077073/ownership.xml","form_type":"4"}},{"id":1323006,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-23T23:32:55.000Z","date":"2024-12-19","kind":"grant","planned":false,"acquired":true,"shares":9077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares issued in lieu of cash compensation under the issuer's non-employee director compensation policy.  All shares vest immediately."}],"balance_after":9077,"source":{"system":"sec-edgar","filing":"0000950170-24-139792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024139792/ownership.xml","form_type":"4"}},{"id":1337418,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T01:46:19.000Z","date":"2024-12-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.4935,"value":7467.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.46 to $1.50 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 QP."}],"balance_after":652573,"source":{"system":"sec-edgar","filing":"0000950170-24-135150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024135150/ownership.xml","form_type":"4"}},{"id":1337417,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T01:46:19.000Z","date":"2024-12-10","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.4924,"value":7462.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.44 to $1.50 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 LP."}],"balance_after":582288,"source":{"system":"sec-edgar","filing":"0000950170-24-135150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024135150/ownership.xml","form_type":"4"}},{"id":1337416,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T01:46:19.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":18483,"price":1.4287,"value":26406.6621,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.41 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 QP."}],"balance_after":647573,"source":{"system":"sec-edgar","filing":"0000950170-24-135150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024135150/ownership.xml","form_type":"4"}},{"id":1337415,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T01:46:19.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":12289,"price":1.4303,"value":17576.9567,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.405 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 LP."}],"balance_after":577288,"source":{"system":"sec-edgar","filing":"0000950170-24-135150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024135150/ownership.xml","form_type":"4"}},{"id":1337414,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T01:46:19.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":6517,"price":1.4466,"value":9427.4922,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.435 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 QP."}],"balance_after":629090,"source":{"system":"sec-edgar","filing":"0000950170-24-135150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024135150/ownership.xml","form_type":"4"}},{"id":1337413,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-11T01:46:19.000Z","date":"2024-12-06","kind":"purchase","planned":false,"acquired":true,"shares":12711,"price":1.445,"value":18367.395,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.40 to $1.45 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 LP."}],"balance_after":564999,"source":{"system":"sec-edgar","filing":"0000950170-24-135150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024135150/ownership.xml","form_type":"4"}},{"id":1349616,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-28T00:07:58.000Z","date":"2024-11-27","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.4167,"value":35417.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.36 to $1.44 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 QP."}],"balance_after":622573,"source":{"system":"sec-edgar","filing":"0000950170-24-131660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024131660/ownership.xml","form_type":"4"}},{"id":1349615,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-28T00:07:58.000Z","date":"2024-11-27","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.4169,"value":35422.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.36 to $1.44 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 LP."}],"balance_after":552288,"source":{"system":"sec-edgar","filing":"0000950170-24-131660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024131660/ownership.xml","form_type":"4"}},{"id":1349614,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-28T00:07:58.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":1.3942,"value":17427.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.38 to $1.409 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 QP."}],"balance_after":597573,"source":{"system":"sec-edgar","filing":"0000950170-24-131660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024131660/ownership.xml","form_type":"4"}},{"id":1349613,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-28T00:07:58.000Z","date":"2024-11-26","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":1.3934,"value":17417.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.3767 to $1.41 per share. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 LP."}],"balance_after":527288,"source":{"system":"sec-edgar","filing":"0000950170-24-131660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024131660/ownership.xml","form_type":"4"}},{"id":1355941,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-21T23:00:10.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.1548,"value":28870.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 LP."}],"balance_after":514788,"source":{"system":"sec-edgar","filing":"0000950170-24-129830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024129830/ownership.xml","form_type":"4"}},{"id":1355940,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-21T23:00:10.000Z","date":"2024-11-20","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.16,"value":29000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 QP."}],"balance_after":585073,"source":{"system":"sec-edgar","filing":"0000950170-24-129830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024129830/ownership.xml","form_type":"4"}},{"id":1355939,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-21T23:00:10.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":1.0364,"value":77730.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.0293 to $1.05. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held directly by MGC 2018 LP."}],"balance_after":489788,"source":{"system":"sec-edgar","filing":"0000950170-24-129830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024129830/ownership.xml","form_type":"4"}},{"id":1355938,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-21T23:00:10.000Z","date":"2024-11-19","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":1.0337,"value":77527.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $1.0211 to $1.05. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC Venture Partners 2018, LP (\"MGC 2018 LP\") and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC 2018 QP."}],"balance_after":560073,"source":{"system":"sec-edgar","filing":"0000950170-24-129830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024129830/ownership.xml","form_type":"4"}},{"id":1472252,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-21T22:22:17.000Z","date":"2024-06-19","kind":"grant","planned":false,"acquired":true,"shares":64503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 19, 2024 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":64503,"derivative":{"exercise_price":2,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":64503},"source":{"system":"sec-edgar","filing":"0000950170-24-076410","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000095017024076410/ownership.xml","form_type":"4"}},{"id":1678115,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-17T22:03:32.000Z","date":"2024-01-12","kind":"sale","planned":true,"acquired":false,"shares":719,"price":21.91,"value":15753.29,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The reported sale of 719 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Shares held directly by MGC 2018 QP."}],"balance_after":485073,"source":{"system":"sec-edgar","filing":"0001209191-24-001770","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000120919124001770/doc4.xml","form_type":"4"}},{"id":1678114,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-17T22:03:32.000Z","date":"2024-01-12","kind":"sale","planned":true,"acquired":false,"shares":706,"price":21.92,"value":15475.52,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 706 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on August 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.96. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by MGC 2018 LP."}],"balance_after":414788,"source":{"system":"sec-edgar","filing":"0001209191-24-001770","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000120919124001770/doc4.xml","form_type":"4"}},{"id":1680156,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-12T22:08:10.000Z","date":"2024-01-10","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":21.92,"value":39456.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The reported sale of 1,800 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC 2018 QP on August 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held directly by MGC 2018 QP."}],"balance_after":485792,"source":{"system":"sec-edgar","filing":"0001209191-24-001537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000120919124001537/doc4.xml","form_type":"4"}},{"id":1680155,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-12T22:08:10.000Z","date":"2024-01-10","kind":"sale","planned":true,"acquired":false,"shares":1869,"price":21.93,"value":40987.17,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale of 1,869 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by MGC Venture Partners 2018, LP (\"MGC 2018 LP\") on August 30, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This price represents the weighted average sale price (rounded to the nearest cent) for multiple transactions reported on this line. The prices of the transactions reported on this line ranged from $21.90 to $21.99. Upon request by the Commission staff, the issuer or a security holder of the issuer, the reporting person will undertake to provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\"). MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held directly by MGC 2018 LP."}],"balance_after":415494,"source":{"system":"sec-edgar","filing":"0001209191-24-001537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000120919124001537/doc4.xml","form_type":"4"}},{"id":1860913,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option\n(right to buy)","published_at":"2023-06-10T00:33:39.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":23742,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shares shall vest on the earlier of (a) the one-year anniversary of June 7, 2023 or (b) the day prior to the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person providing continuous service through such vesting date."}],"balance_after":23742,"derivative":{"exercise_price":5.91,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":23742},"source":{"system":"sec-edgar","filing":"0000899243-23-015307","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924323015307/doc4.xml","form_type":"4"}},{"id":2270606,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-17T01:25:12.000Z","date":"2022-05-12","kind":"grant","acquired":true,"shares":20724,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest as follows: 1/36 of the shares shall vest on each monthly anniversary as measured from March 25, 2022."}],"balance_after":20724,"derivative":{"exercise_price":17.28,"expiration_date":"2032-05-11","underlying":"Common Stock","underlying_shares":20724},"source":{"system":"sec-edgar","filing":"0000899243-22-018293","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322018293/doc4.xml","form_type":"4"}},{"id":2313141,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":71839,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":71839},"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313140,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":61491,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by MGC Venture Partners 2018, LP. (\"MGC 2018 LP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":61491},"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313139,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":333135,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":333135},"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313138,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":false,"shares":285156,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by MGC Venture Partners 2018, LP. (\"MGC 2018 LP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":285156},"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313137,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":82618,"price":15,"value":1239270.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":487592,"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313136,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"purchase","acquired":true,"shares":70716,"price":15,"value":1060740.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by MGC Venture Partners 2018, LP. (\"MGC 2018 LP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":417363,"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313135,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":71839,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":404974,"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313134,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":61491,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by MGC Venture Partners 2018, LP. (\"MGC 2018 LP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":346647,"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313133,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":333135,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held directly by MGC Venture Partners QP 2018 LP (\"MGC 2018 QP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":333135,"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}},{"id":2313132,"issuer":{"id":1085,"kind":"organization","name":"AN2 Therapeutics, Inc.","symbol":"ANTX"},"owners":[{"id":21691,"kind":"person","name":"Readnour Robin Shane","position":1,"cik":"0001914883","reported_name":"Readnour Robin Shane","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-01T00:15:32.000Z","date":"2022-03-29","kind":"exercise","acquired":true,"shares":285156,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the \"IPO\"), for no additional consideration. The shares of Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held directly by MGC Venture Partners 2018, LP. (\"MGC 2018 LP\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"MGC Venture Partners 2018 GP, LLC (\"MGC 2018 GP\") is the general partner of MGC 2018 LP and MGC 2018 QP. MGC 2018 GP has shared voting and shared dispositive power over the shares held by MGC 2018 LP and MGC 2018 QP. The Reporting Person is a member of the Issuer's board of directors and is a member of MGC 2018 QP and MGC 2018 LP and a managing partner of MGC 2018 GP and has shared voting power and shared dispositive power over the shares of common stock held by MGC 2018 LP and MGC 2018 QP. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of such person's pecuniary interest in such securities."}],"balance_after":285156,"source":{"system":"sec-edgar","filing":"0000899243-22-012991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1880438/000089924322012991/doc4.xml","form_type":"4"}}]}